GuidelineBlood advances2019
2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations.
Guideline in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2025Guideline
- American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.Blood advances · 2021Guideline
- American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.Blood advances · 2020Guideline
- Usage of a Multipurpose mHealth App Among Adults With Sickle Cell Disease: Randomized Controlled Trial.JMIR formative research · 2025Trial
- A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD.Blood advances · 2023Trial
- A Statewide Recommendation for Opt-Out Syphilis Screening in Nonpregnant Adults: Rationale and Evidence-to-Decision Framework.AJPM focus · 2026Article
- Barriers and Facilitators to Interest-Holder Engagement in Health Guideline Development: A Qualitative Evidence Synthesis.Campbell systematic reviews · 2026Review
- Article
- ASH sickle cell disease CPKD guidelines report.Blood advances · 2025Article
- Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions.Nutrients · 2024Review
- Transcranial Doppler ultrasonography in patients with hemoglobinopathy: An experience from a tertiary center.Northern clinics of Istanbul · 2022Article
- How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines.Blood advances · 2021Article
- Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.European journal of haematology · 2021Article
- American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.Blood advances · 2020Article
- Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.Blood advances · 2020Article
- American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The American Society of Hematology (ASH) convened 5 guideline panels to develop clinical practice recommendations addressing 5 management areas of highest importance to individuals living with sickle cell disease: pain, cerebrovascular complications, pulmonary and kidney complications, transfusion, and hematopoietic stem cell transplant. Panels were multidisciplinary and consisted of patient representatives, content experts, and methodologists. The Mayo Clinic Evidence-Based Practice Center conducted systematic reviews based on a priori selected questions. In this exposition, we describe the process used by ASH, including the GRADE approach (Grades of Recommendations, Assessment, Development and Evaluation) for rating certainty of the evidence and the GRADE Evidence to Decision Framework. We also describe several unique challenges faced by the guideline panels and the specific innovations and solutions used to address them, including a curriculum to train patients to engage in guideline development, dealing with the opioid crisis, and working with indirect and noncomparative evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.